I
Immuno-Biological Laboratories
Immuno-Biological Laboratories is developing, manufacturing and supplying various immunological research reagents, and customized services
About Immuno-Biological Laboratories
IBL Japan is a leading provider of customized antibodies and ELISA kits, catering primarily to pharmaceutical companies and diagnostic product manufacturers. Operating within the biotechnology sector, the company focuses on developing and supplying high-quality antibodies and diagnostic kits that meet stringent quality control standards, including ISO 13485 certification. IBL Japan's business model revolves around both product sales and contract services, generating revenue through the sale of proprietary diagnostic kits and customized antibody solutions. The company also engages in licensing agreements for antibody drugs, aiming to discover and develop valuable biological markers for therapeutic use. By maintaining a robust R&D pipeline and collaborating with international business partners, IBL Japan ensures its offerings remain at the forefront of scientific innovation.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2007
- Open positions
- None listed
- Dealroom signal
- 24.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Arts & Culture
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO DEBT✓Debt | Dec 2016 | $11M | — | Whiz Partners | — |
| IPO✓Exit | Mar 2007 | $0 | — | Undisclosed | — |
Growth signals
Latest recorded traffic for Immuno-Biological Laboratories is 5.1K monthly website visits, down 49% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Immuno-Biological Laboratories in its local ecosystem
The Immuno-Biological Laboratories office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
Whiz Partners
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Immuno-Biological Laboratories on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Immuno-Biological Laboratories’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









